Advertisement

Stem Cell Reviews and Reports

, Volume 9, Issue 1, pp 80–92 | Cite as

Mesenchymal Stem Cell: Does it Work in an Experimental Model with Acute Respiratory Distress Syndrome?

  • Sema YilmazEmail author
  • Nihal Inandiklioglu
  • Dincer Yildizdas
  • Cansu Subasi
  • Arbil Acikalin
  • Yurdun Kuyucu
  • Ibrahim Bayram
  • Ali Topak
  • Atila Tanyeli
  • Gokhan Duruksu
  • Erdal KaraozEmail author
Article

Abstract

We hypothesized that bone marrow-derived mesenchymal stem cells (BM-MSCs) would have a possible role in the treatment of acute respiratory distress syndrome (ARDS). ARDS disease model was developed in Wistar albino male rats by intratracheal instillation of physiological saline solution. Anesthezied and tracheotomized rats (n = 8) with ARDS were pressure-controlled ventilated. Isolated and characterized rat (r-) BM-MSCs were labeled with GFP gene, and introduced in the lungs of the ARDS rat-model. After applying of MSCs, the life span of each rat was recorded. When rats died, their lung tissues were removed for histopathological examination. Also the tissue sections were analyzed for GFP labeled rBM-MSCs and stained for vimentin, CK19, proinflammatory (MPO, IL-1β, IL-6 and MIP-2) and anti-inflammatory [IL-1ra and prostaglandin E2 receptor (EP3)] cytokines. The histopathological signs of rat-model ARDS were similar to the acute phase of ARDS in humans. rBM-MSCs were observed to home in lung paranchyma. Although the infiltration of neutrophils slightly decreased in the interalveolar, peribronchial and perivascular area, a notable improvement was determined in the degree of hemorrhage, edema and hyaline membrane formation in rats treated with rBM-MSCs. Also decreased proinflammatory cytokines levels and increased the intensity of anti-inflammatory cytokines were established. Therefore MSCs could promote alveoar epithelial repair by mediating of cytokines from a proinflammatory to an anti-inflammatory response. As a novel therapeutic approach, mesenchymal stem cell treatment with intratracheal injection could be helpful in the management of critically ill patients with ARDS.

Keywords

Acute respiratory distress syndrome Mesenchymal stem cell Cytokine Inflammation Critically ill 

Notes

Acknowledgment

This work was supported by the Cukurova University Research (TF2011BAP20) Fund. The authors thank Kezban Bostaner, Recep Mutlu and Gizem Turaç for their technical assistance. We also express our gratitude to Dr. Gökhan Duruksu for editing of this manuscript.

Conflict of Interest Statement

None of the authors have a financial relationship with a commercial entity that has an interest in the subject of this manuscript.

References

  1. 1.
    Ware, L. B., & Matthay, M. A. (2000). The acute respiratory distress syndrome. The New England Journal of Medicine, 342(18), 1334–1349.PubMedCrossRefGoogle Scholar
  2. 2.
    Bernard, G. R., Artigas, A., Brigham, K. L., et al. (1994). Report of the American-European consensus conference on ARDS: definitions, mechanisms, relevant outcomes and clinical trial coordination. The Consensus Committee. Intensıve Care Medicine, 20(3), 225–232.PubMedCrossRefGoogle Scholar
  3. 3.
    Tomashefski, J. F., Jr. (2000). Pulmonary pathology of acute respiratory distress syndrome. Clinics in Chest Medicine, 21(3), 435–466.PubMedCrossRefGoogle Scholar
  4. 4.
    Matthay, M. A., & Zemans, R. L. (2011). The acute respiratory distress syndrome: pathogenesis and treatment. Annual Review of Pathology, 6, 147–163.PubMedCrossRefGoogle Scholar
  5. 5.
    Dushianthan, A., Grocott, M. P., Postle, A. D., & Cusack, R. (2011). Acute respiratory distress syndrome and acute lung injury. Postgraduate Medical Journal, 87(1031), 612–622.PubMedCrossRefGoogle Scholar
  6. 6.
    Calfee, C. S., & Matthay, M. A. (2007). Nonventilatory treatments for acute lung injury and ARDS. Chest, 131(3), 913–920.PubMedCrossRefGoogle Scholar
  7. 7.
    Cepkova, M., & Matthay, M. A. (2006). Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome. Journal of Intensive Care Medicine, 21(3), 119–143.PubMedCrossRefGoogle Scholar
  8. 8.
    Rojas, M., Xu, J., Woods, C. R., et al. (2005). Bone marrow-derived mesenchymal stem cells in repair of the injured lung. American Journal of Respiratory Cell and Molecular Biology, 33(2), 145–152.PubMedCrossRefGoogle Scholar
  9. 9.
    Dominici, M., Le Blanc, K., Mueller, I., et al. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy, 8(4), 315–317.PubMedCrossRefGoogle Scholar
  10. 10.
    Ortiz, L. A., Gambelli, F., McBride, C., et al. (2003). Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proceedings of the National Academy of Sciences, 100, 8407–8411.CrossRefGoogle Scholar
  11. 11.
    Patel, S. A., Sherman, L., Munoz, J., & Rameshwar, P. (2008). Immunological properties of mesenchymal stem cells and clinical implications. Archivum Immunologiae et Therapiae Experimentalis, 56(1), 1–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Germann, P. G., & Häfner, D. (1998). A rat model of acute respiratory distress syndrome (ARDS): part 1. Time dependency of histological and pathological changes. Journal of Pharmacological and Toxicological Methods, 40(2), 101–107.PubMedCrossRefGoogle Scholar
  13. 13.
    Häfner, D., & Germann, P. G. (1999). A rat model of acute respiratory distress syndrome (ARDS) part 2, influence of lavage volume, lavage repetition, and therapeutic treatment with rSP-C surfactant. Journal of Pharmacological and Toxicological Methods, 41(2–3), 97–106.PubMedCrossRefGoogle Scholar
  14. 14.
    Gupta, N., Su, X., Popov, B., Lee, J. W., Serikov, V., & Matthay, M. A. (2007). Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. Journal of Immunology, 179(3), 1855–1863.Google Scholar
  15. 15.
    Lee, J. W., Gupta, N., Serikov, V., & Matthay, M. A. (2009). Potential application of mesenchymal stem cells in acute lung injury. Expert Opinion on Biological Therapy, 9(10), 1259–1270.PubMedCrossRefGoogle Scholar
  16. 16.
    Sinclair, D. G., Braude, S., Haslam, P. L., & Evans, T. W. (1994). Pulmonary endothelial permeability in patients with severe lung injury. Clinical correlates and natural history. Chest, 106(2), 535–539.PubMedCrossRefGoogle Scholar
  17. 17.
    Xu, J., Qu, J., Cao, L., et al. (2008). Mesenchymal stem cell-based angiopoietin-1 gene therapy for acute lung injury induced by lipopolysaccharide in mice. The Journal of Pathology, 214, 472–481.PubMedCrossRefGoogle Scholar
  18. 18.
    Lee, J. W., Fang, X., Gupta, N., Serikov, V., & Matthay, M. A. (2009). Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proceedings of the National Academy of Sciences, 106(38), 16357–16362.CrossRefGoogle Scholar
  19. 19.
    Fang, X., Neyrinck, A. P., Matthay, M. A., & Lee, J. W. (2010). Allogeneic human mesenchymal stem cells restore epithelial protein permeability in cultured human alveolar type II cells by secretion of angiopoietin-1. Journal of Biological Chemistry, 285(34), 26211–26222.PubMedCrossRefGoogle Scholar
  20. 20.
    Stewart, D. J., & Mei, S. H. (2011). Cell-based therapies for lung vascular diseases: lessons for the future. Proceedings of the American Thoracic Society, 8(6), 535–540.PubMedCrossRefGoogle Scholar
  21. 21.
    Aggarwal, S., & Pittenger, M. F. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, 105(4), 1815–1822.PubMedCrossRefGoogle Scholar
  22. 22.
    Corcione, A., Benvenuto, F., Ferretti, E., et al. (2006). Human mesenchymal stem cells modulate B-cell functions. Blood, 107(1), 367–372.PubMedCrossRefGoogle Scholar
  23. 23.
    Bouffi, C., Bony, C., Courties, G., Jorgensen, C., & Noël, D. (2010). IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS One, 5(12), e14247.PubMedCrossRefGoogle Scholar
  24. 24.
    Lee, J. W., Fang, X., Krasnodembskaya, A., Howard, J. P., & Matthay, M. A. (2011). Concise review: mesenchymal stem cells for acute lung injury: role of paracrine soluble factors. Stem Cells, 29(6), 913–919.PubMedCrossRefGoogle Scholar
  25. 25.
    Takaoka, Y., Niwa, S., & Nagai, H. (1999). Interleukin-1beta induces interleukin-6 production through the production of prostaglandin E (2) in human osteoblasts, MG-63 cells. Journal of Biochemistry, 126(3), 553–558.PubMedCrossRefGoogle Scholar
  26. 26.
    Geiser, T., Atabai, K., Jarreau, P. H., Ware, L. B., Pugin, J., & Matthay, M. A. (2001). Pulmonary edema fluid from patients with acute lung injury augments in vitro alveolar epithelial repair by an il-1beta-dependent mechanism. American Journal of Respiratory and Critical Care Medicine, 163(6), 1384–1388.PubMedGoogle Scholar
  27. 27.
    Chimenti, L., Luque, T., Bonsignore, M. R., Ramírez, J., Navajas, D., & Farré, R. (2012). Pre-treatment with mesenchymal stem cells reduces ventilator-induced lung injury. European Respiratory Journal. doi: 10.1183/09031936.00153211.
  28. 28.
    Raffaghello, L., Bianchi, G., Bertolotto, M., et al. (2008). Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells, 26, 151–162.PubMedCrossRefGoogle Scholar
  29. 29.
    Tai, W. L., Dong, Z. X., Zhang, D. D., & Wang, D. H. (2012). Therapeutic effect of intravenous bone marrow-derived mesenchymal stem cell transplantation on early-stage LPS-induced acute lung injury in mice. Nan Fang Yi Ke Da Xue Xue Bao, 32(3), 283–290.PubMedGoogle Scholar
  30. 30.
    Nemeth, K., Leelahavanichkul, A., Yuen, P. S., et al. (2009). Bone marrow stromal cells attenuate sepsis via prostaglandin E (2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nature Medicine, 15(1), 42–49.PubMedCrossRefGoogle Scholar
  31. 31.
    Volarevic, V., Al-Qahtani, A., Arsenijevic, N., Pajovic, S., & Lukic, M. L. (2010). Interleukin-1 receptor antagonist (IL-1Ra) and IL-1Ra producing mesenchymal stem cells as modulators of diabetogenesis. Autoimmunity, 43(4), 255–263.PubMedCrossRefGoogle Scholar
  32. 32.
    Ortiz, L. A., Dutreil, M., Fattman, C., et al. (2007). Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proceedings of the National Academy of Sciences, 104(26), 11002–11007.CrossRefGoogle Scholar
  33. 33.
    Kleiveland, C. R., Kassem, M., & Lea, T. (2008). Human mesenchymal stem cell proliferation is regulated by PGE2 through differential activation of cAMP-dependent protein kinase isoforms. Experimental Cell Research, 314(8), 1831–1838.PubMedCrossRefGoogle Scholar
  34. 34.
    Bunnell, B. A., Betancourt, A. M., & Sullivan, D. E. (2010). New concepts on the immune modulation mediated by mesenchymal stem cells. Stem Cell Research and Therapy, 1(5), 34.PubMedCrossRefGoogle Scholar
  35. 35.
    Wu, L., Wang, Q., Liang, X., & Andreasson, K. (2007). Divergent effects of prostaglandin receptor signaling on neuronal survival. Neuroscience Letters, 421(3), 253–258.PubMedCrossRefGoogle Scholar
  36. 36.
    Moore, B. B., Ballinger, M. N., White, E. S., et al. (2005). Bleomycin-induced E prostanoid receptor changes alter fibroblast responses to prostaglandin E2. Journal of Immunology, 174(9), 5644–5649.Google Scholar
  37. 37.
    Barbash, I. M., Chouraqui, P., Baron, J., et al. (2003). Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation, 108(7), 863–868.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Sema Yilmaz
    • 1
    Email author
  • Nihal Inandiklioglu
    • 2
  • Dincer Yildizdas
    • 3
  • Cansu Subasi
    • 4
  • Arbil Acikalin
    • 5
  • Yurdun Kuyucu
    • 6
  • Ibrahim Bayram
    • 7
  • Ali Topak
    • 8
  • Atila Tanyeli
    • 7
  • Gokhan Duruksu
    • 9
  • Erdal Karaoz
    • 4
    Email author
  1. 1.Department of Pediatric Hematology/OncologyOndokuz Mayıs University Faculty of MedicineAtakumTurkey
  2. 2.Department of Medical BiologyCukurova University Faculty of MedicineAdanaTurkey
  3. 3.Department of Pediatric Intensive Care UnitCukurova University Faculty of MedicineAdanaTurkey
  4. 4.Institute of Health Sciences, Stem Cell DepartmentKocaeli University Center for Stem Cell and Gene Therapies Research and PracticeUmuttepe-İzmitTurkey
  5. 5.Department of PathologyCukurova University Medical FacultyAdanaTurkey
  6. 6.Department of HistologyCukurova University Faculty of MedicineAdanaTurkey
  7. 7.Department of Pediatric Hematology/OncologyCukurova University Faculty of MedicineAdanaTurkey
  8. 8.Department of Experimental Research and Practice Center of MedicalCukurova University Faculty of MedicineAdanaTurkey
  9. 9.Institute fo Health Sciences,Stem Cell DepartmentKocaeli University Center for Stem Cell and Gene Therapies research and PracticeAdanaTurkey

Personalised recommendations